US20090155176A1 - Compositions and methods for treatment of diabetic retinopathy - Google Patents
Compositions and methods for treatment of diabetic retinopathy Download PDFInfo
- Publication number
- US20090155176A1 US20090155176A1 US12/288,330 US28833008A US2009155176A1 US 20090155176 A1 US20090155176 A1 US 20090155176A1 US 28833008 A US28833008 A US 28833008A US 2009155176 A1 US2009155176 A1 US 2009155176A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- aryl
- lfa
- substituted
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C([C@](CN(CN(C1)S([C@@]2*C2)(=O)=O)C1=O)NC(c(c(*)cc(C1)c2CCN1C(c(cc1)ccc1Cl)=O)c2Cl)=O)=O Chemical compound *C([C@](CN(CN(C1)S([C@@]2*C2)(=O)=O)C1=O)NC(c(c(*)cc(C1)c2CCN1C(c(cc1)ccc1Cl)=O)c2Cl)=O)=O 0.000 description 62
- GZNSDMIIWVTTGZ-UHFFFAOYSA-N C1=CC=CC=C1.C1=CC=CC=C1.CC.CC.CC.CC.CC(C)=O.CC(C)=O.S Chemical compound C1=CC=CC=C1.C1=CC=CC=C1.CC.CC.CC.CC.CC(C)=O.CC(C)=O.S GZNSDMIIWVTTGZ-UHFFFAOYSA-N 0.000 description 3
- TXMQWCSDBNIECG-UHFFFAOYSA-N CC1=CC(O)=CC=C1.CC1=CC=C2C=COC2=C1.CC1=CC=C2C=NNC2=C1.CC1=NN2C=CC=CC2=C1 Chemical compound CC1=CC(O)=CC=C1.CC1=CC=C2C=COC2=C1.CC1=CC=C2C=NNC2=C1.CC1=NN2C=CC=CC2=C1 TXMQWCSDBNIECG-UHFFFAOYSA-N 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N S Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- YCZZREUPDHJTIU-UHFFFAOYSA-N CC1=CC2=C(C=C1)NC=C2.CC1=CC2=C(C=CC=C2)N=C1.CC1=CC2=C(C=CN2)C=C1 Chemical compound CC1=CC2=C(C=C1)NC=C2.CC1=CC2=C(C=CC=C2)N=C1.CC1=CC2=C(C=CN2)C=C1 YCZZREUPDHJTIU-UHFFFAOYSA-N 0.000 description 2
- XPCCOWZFTCVMMC-FQEVSTJZSA-N CC1=CC2=C(C=NN(CC3=CC=CC=C3)C2=O)C=C1C(=O)N[C@@H](CNC(=O)C1=CC=CS1)C(=O)O Chemical compound CC1=CC2=C(C=NN(CC3=CC=CC=C3)C2=O)C=C1C(=O)N[C@@H](CNC(=O)C1=CC=CS1)C(=O)O XPCCOWZFTCVMMC-FQEVSTJZSA-N 0.000 description 2
- OAODYERIJMLJCY-YSMBQZINSA-N CCN1C(=O)/C(=C/C=C[Y])SC1=S.I Chemical compound CCN1C(=O)/C(=C/C=C[Y])SC1=S.I OAODYERIJMLJCY-YSMBQZINSA-N 0.000 description 2
- UIQHPJBLRPBJON-QFIPXVFZSA-N CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)=C1 UIQHPJBLRPBJON-QFIPXVFZSA-N 0.000 description 2
- ZKROHHMQLBCXHF-ORLSSACPSA-N CS(=O)C1=CC(F)=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)=C1 Chemical compound CS(=O)C1=CC(F)=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)=C1 ZKROHHMQLBCXHF-ORLSSACPSA-N 0.000 description 2
- DFYLLKBBGKQNMR-UHFFFAOYSA-N Cc1n[n](cccc2)c2c1 Chemical compound Cc1n[n](cccc2)c2c1 DFYLLKBBGKQNMR-UHFFFAOYSA-N 0.000 description 2
- DVPHHFRHUYBSCI-UHFFFAOYSA-N C.C.CCCCN1CCOCC1.CCCN1CCOCC1 Chemical compound C.C.CCCCN1CCOCC1.CCCN1CCOCC1 DVPHHFRHUYBSCI-UHFFFAOYSA-N 0.000 description 1
- IWAUZRCLFRTVAA-UHFFFAOYSA-N C.CC.CC.CC.CC(C)C1=CC=CC=C1.CC(C)C1=CC=NC=C1.CC(C)C1=NC=CC=C1 Chemical compound C.CC.CC.CC.CC(C)C1=CC=CC=C1.CC(C)C1=CC=NC=C1.CC(C)C1=NC=CC=C1 IWAUZRCLFRTVAA-UHFFFAOYSA-N 0.000 description 1
- YTYHYJZVTFNFDL-FQEVSTJZSA-N C=C(C)C1=CN(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)N=N1 Chemical compound C=C(C)C1=CN(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)N=N1 YTYHYJZVTFNFDL-FQEVSTJZSA-N 0.000 description 1
- UXHCTURHOPIBDF-IBGZPJMESA-N CC(=O)(=O)NCCC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C3C=COC3=C1)CC2)C(=O)O Chemical compound CC(=O)(=O)NCCC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C3C=COC3=C1)CC2)C(=O)O UXHCTURHOPIBDF-IBGZPJMESA-N 0.000 description 1
- LOYOFAAWCUHLHK-BGERDNNASA-N CC(=O)[C@H](CNC(=O)C1=CC=CS1)NC(=O)C1=C(Cl)C=C(CCC(O)C2=CC(O)=CC=C2)C=C1Cl Chemical compound CC(=O)[C@H](CNC(=O)C1=CC=CS1)NC(=O)C1=C(Cl)C=C(CCC(O)C2=CC(O)=CC=C2)C=C1Cl LOYOFAAWCUHLHK-BGERDNNASA-N 0.000 description 1
- OIONHJWHMYXBIQ-HZBRMTLQSA-N CC(C)(C)/C(/C)=C(\C(C=C)=N)/N Chemical compound CC(C)(C)/C(/C)=C(\C(C=C)=N)/N OIONHJWHMYXBIQ-HZBRMTLQSA-N 0.000 description 1
- NFHXWCPPKPQNOC-FQEVSTJZSA-N CC(C)N1C=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)N=N1 Chemical compound CC(C)N1C=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)N=N1 NFHXWCPPKPQNOC-FQEVSTJZSA-N 0.000 description 1
- PZZSUSOQPCMUND-UHFFFAOYSA-N CC(O1)=C(COC)OC1=O Chemical compound CC(O1)=C(COC)OC1=O PZZSUSOQPCMUND-UHFFFAOYSA-N 0.000 description 1
- ATRLVVVJFBQMEX-UHFFFAOYSA-N CC1(C)OC(COC)CO1 Chemical compound CC1(C)OC(COC)CO1 ATRLVVVJFBQMEX-UHFFFAOYSA-N 0.000 description 1
- KWZHUKPBTPPJBV-NRFANRHFSA-N CC1=C(S(C)(=O)=O)C=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)O1 Chemical compound CC1=C(S(C)(=O)=O)C=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)O1 KWZHUKPBTPPJBV-NRFANRHFSA-N 0.000 description 1
- NUTVILKQFHBQPF-NRFANRHFSA-N CC1=CC2=C(C=C1C(=O)N[C@@H](CNC(=O)C1=CC=CS1)C(=O)O)CCN(CC1=CC=CC=C1)C2=O Chemical compound CC1=CC2=C(C=C1C(=O)N[C@@H](CNC(=O)C1=CC=CS1)C(=O)O)CCN(CC1=CC=CC=C1)C2=O NUTVILKQFHBQPF-NRFANRHFSA-N 0.000 description 1
- SWCGUWBRFSJVPE-HFZDXXHNSA-N CC1=CC=C([C@@H]2CN(C3=CC=C(C(=O)O)C=N3)C[C@]23C(=O)N(C2=CC(Cl)=CC(Cl)=C2)C(=O)N3C)C=C1 Chemical compound CC1=CC=C([C@@H]2CN(C3=CC=C(C(=O)O)C=N3)C[C@]23C(=O)N(C2=CC(Cl)=CC(Cl)=C2)C(=O)N3C)C=C1 SWCGUWBRFSJVPE-HFZDXXHNSA-N 0.000 description 1
- GWHPNSOKATYUBZ-QFIPXVFZSA-N CCC1=C(C(=O)N[C@@H](CNC(=O)C2=CC=CS2)C(=O)O)C2=C(C=CC=C2)N(CCCC2=CC=CC=C2)C1=O Chemical compound CCC1=C(C(=O)N[C@@H](CNC(=O)C2=CC=CS2)C(=O)O)C2=C(C=CC=C2)N(CCCC2=CC=CC=C2)C1=O GWHPNSOKATYUBZ-QFIPXVFZSA-N 0.000 description 1
- LMRKVKPRHROQRR-UHFFFAOYSA-N CCCCN1CCOCC1 Chemical compound CCCCN1CCOCC1 LMRKVKPRHROQRR-UHFFFAOYSA-N 0.000 description 1
- NMILGIZTAZXMTM-UHFFFAOYSA-N CCCN1CCOCC1 Chemical compound CCCN1CCOCC1 NMILGIZTAZXMTM-UHFFFAOYSA-N 0.000 description 1
- XWXMOIBPFQPGNQ-DHDCSXOGSA-N CCN1C(=O)/C(=C/C2=CC=C(C3=C(C)C(Cl)=CC=C3)O2)SC1=S Chemical compound CCN1C(=O)/C(=C/C2=CC=C(C3=C(C)C(Cl)=CC=C3)O2)SC1=S XWXMOIBPFQPGNQ-DHDCSXOGSA-N 0.000 description 1
- GSMFAEYNTKIQCU-QHCPKHFHSA-N CN1CCN(C(=O)[C@H](CNC(=O)C2=CC=CS2)NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)CC1 Chemical compound CN1CCN(C(=O)[C@H](CNC(=O)C2=CC=CS2)NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)CC1 GSMFAEYNTKIQCU-QHCPKHFHSA-N 0.000 description 1
- OIIJJGAFRGJQSQ-UHFFFAOYSA-N COC(c1ccccc11)OC1=O Chemical compound COC(c1ccccc11)OC1=O OIIJJGAFRGJQSQ-UHFFFAOYSA-N 0.000 description 1
- YVDHLZCIARJPRY-NQIIRXRSSA-N COC1=C(C2=CC(Cl)=CC(C)=C2)S(=O)(=O)N2C[C@H](O)C[C@@]12CC1=CC=C(Br)C=C1 Chemical compound COC1=C(C2=CC(Cl)=CC(C)=C2)S(=O)(=O)N2C[C@H](O)C[C@@]12CC1=CC=C(Br)C=C1 YVDHLZCIARJPRY-NQIIRXRSSA-N 0.000 description 1
- NYFCMQOONXYPTH-UHFFFAOYSA-N COC1COCC1 Chemical compound COC1COCC1 NYFCMQOONXYPTH-UHFFFAOYSA-N 0.000 description 1
- JBBDDNUWYXTKTL-QHCPKHFHSA-N CS(=O)(=O)C1=CC(F)=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CC(F)=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)=C1 JBBDDNUWYXTKTL-QHCPKHFHSA-N 0.000 description 1
- ZCUVWGWFWZZPJK-IBGZPJMESA-N CS(=O)(=O)C1=CC=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(N=CC=C4)N2)CC3)C(=O)O)O1 Chemical compound CS(=O)(=O)C1=CC=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(N=CC=C4)N2)CC3)C(=O)O)O1 ZCUVWGWFWZZPJK-IBGZPJMESA-N 0.000 description 1
- PXWKZXMPCCTSLZ-FQEVSTJZSA-N CS(=O)(=O)C1=CC=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)O1 Chemical compound CS(=O)(=O)C1=CC=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)O1 PXWKZXMPCCTSLZ-FQEVSTJZSA-N 0.000 description 1
- GWWFFDYTJMVBBN-GTCGAKFVSA-N CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)/C=C/C2=C(F)C=CC=C2)CC3)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)/C=C/C2=C(F)C=CC=C2)CC3)C(=O)O)=C1 GWWFFDYTJMVBBN-GTCGAKFVSA-N 0.000 description 1
- KISBWEONOKGVMR-FMLSYUSBSA-N CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)/C=C/C2=CC=CC=C2)CC3)C(=O)O)=C1.CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(C=C2)CCO4)CC3)C(=O)O)=C1.CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)=C1.CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=NNC4=C2)CC3)C(=O)O)=C1.N#CNC(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=NN3=C(=C1)C=CC=C3)CC2)C(=O)O)N1CC[C@H](O)C1.O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC3=C(C=CO3)C=C1)CC2)C(=O)O)C1=CC=CS1 Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)/C=C/C2=CC=CC=C2)CC3)C(=O)O)=C1.CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(C=C2)CCO4)CC3)C(=O)O)=C1.CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)=C1.CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=NNC4=C2)CC3)C(=O)O)=C1.N#CNC(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=NN3=C(=C1)C=CC=C3)CC2)C(=O)O)N1CC[C@H](O)C1.O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC3=C(C=CO3)C=C1)CC2)C(=O)O)C1=CC=CS1 KISBWEONOKGVMR-FMLSYUSBSA-N 0.000 description 1
- XTBPSAJHDAGGRH-QHCPKHFHSA-N CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(C=C2)C=NN4)CC3)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(C=C2)C=NN4)CC3)C(=O)O)=C1 XTBPSAJHDAGGRH-QHCPKHFHSA-N 0.000 description 1
- PVQJCLRSEKNEMM-DEOSSOPVSA-N CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(C=CC=C4)N2)CC3)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(C=CC=C4)N2)CC3)C(=O)O)=C1 PVQJCLRSEKNEMM-DEOSSOPVSA-N 0.000 description 1
- JFOZKMSJYSPYLN-QHCPKHFHSA-N CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(C=CO4)C=C2)CC3)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(C=CO4)C=C2)CC3)C(=O)O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 1
- VVJCMAGXMXSTSJ-QFIPXVFZSA-N CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(N=CC=C4)N2)CC3)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC4=C(N=CC=C4)N2)CC3)C(=O)O)=C1 VVJCMAGXMXSTSJ-QFIPXVFZSA-N 0.000 description 1
- PEXQHAVIAHUOJX-VWLOTQADSA-N CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=NC=C4C=CC=CC4=C2)CC3)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=NC=C4C=CC=CC4=C2)CC3)C(=O)O)=C1 PEXQHAVIAHUOJX-VWLOTQADSA-N 0.000 description 1
- AGYAXZQEHHTFSZ-NQCNTLBGSA-N CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C=C(CCC(O)C3=CC=C(Cl)C=C3)C=C2Cl)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C=C(CCC(O)C3=CC=C(Cl)C=C3)C=C2Cl)C(=O)O)=C1 AGYAXZQEHHTFSZ-NQCNTLBGSA-N 0.000 description 1
- XEUWPWPYWNZFKU-CZQLGGELSA-N CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C=C(CNC(=O)/C=C/C3=C(O)C=CC=C3)C=C2Cl)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C=C(CNC(=O)/C=C/C3=C(O)C=CC=C3)C=C2Cl)C(=O)O)=C1 XEUWPWPYWNZFKU-CZQLGGELSA-N 0.000 description 1
- MLXOTQPKGPDXFB-AWEZNQCLSA-N CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C=CC=C2Cl)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C=CC=C2Cl)C(=O)O)=C1 MLXOTQPKGPDXFB-AWEZNQCLSA-N 0.000 description 1
- SFARGWXZNDJSSS-NRFANRHFSA-N CS(=O)(=O)C1=CN(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)C=C1 Chemical compound CS(=O)(=O)C1=CN(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)C=C1 SFARGWXZNDJSSS-NRFANRHFSA-N 0.000 description 1
- VNBHPAJREIIVSS-QFIPXVFZSA-N CS(=O)(=O)C1=CN=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)=C1 Chemical compound CS(=O)(=O)C1=CN=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)=C1 VNBHPAJREIIVSS-QFIPXVFZSA-N 0.000 description 1
- HSQGYERCZWAZRE-SFHVURJKSA-N CS(=O)(=O)C1=NC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)=CN1 Chemical compound CS(=O)(=O)C1=NC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)=CN1 HSQGYERCZWAZRE-SFHVURJKSA-N 0.000 description 1
- YLGKILIQQAMXNJ-SFHVURJKSA-N CS(=O)(=O)CCNC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C(Cl)C=C1)CC2)C(=O)O Chemical compound CS(=O)(=O)CCNC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C(Cl)C=C1)CC2)C(=O)O YLGKILIQQAMXNJ-SFHVURJKSA-N 0.000 description 1
- ZSAWXUVSKNFTNR-YVSHKSEASA-N CS(=O)(=O)N1C=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)/C=C/C2=CC=CO2)CC3)C(=O)O)C2=C1C=CC=C2 Chemical compound CS(=O)(=O)N1C=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)/C=C/C2=CC=CO2)CC3)C(=O)O)C2=C1C=CC=C2 ZSAWXUVSKNFTNR-YVSHKSEASA-N 0.000 description 1
- PJTWPYWVBWVBCI-QFIPXVFZSA-N CS(=O)(=O)N1CCC=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)C1 Chemical compound CS(=O)(=O)N1CCC=C(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)C1 PJTWPYWVBWVBCI-QFIPXVFZSA-N 0.000 description 1
- QAQQIDOGRVTSTF-QFIPXVFZSA-N CS(=O)(=O)NC1=C(NC[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(NC[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C(Cl)C=C2)CC3)C(=O)O)C=CC=C1 QAQQIDOGRVTSTF-QFIPXVFZSA-N 0.000 description 1
- CMVMPRRSIRJGRR-WRBCOKKTSA-N CS(=O)C1=CN=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)=C1 Chemical compound CS(=O)C1=CN=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)=C1 CMVMPRRSIRJGRR-WRBCOKKTSA-N 0.000 description 1
- PRPHVKJRIAHCRF-OWJWWREXSA-N C[C@H](O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=NNC4=C2)CC3)C(=O)O)=CC=C1 Chemical compound C[C@H](O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=NNC4=C2)CC3)C(=O)O)=CC=C1 PRPHVKJRIAHCRF-OWJWWREXSA-N 0.000 description 1
- WRQPRKSFJUDQOS-DEOSSOPVSA-N C[SH](C)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)=C1 Chemical compound C[SH](C)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(C=C2Cl)CN(C(=O)C2=CC=C4C=COC4=C2)CC3)C(=O)O)=C1 WRQPRKSFJUDQOS-DEOSSOPVSA-N 0.000 description 1
- HMMPHXCOTBASBC-UHFFFAOYSA-N Cc1cc([nH]nc2)c2cc1 Chemical compound Cc1cc([nH]nc2)c2cc1 HMMPHXCOTBASBC-UHFFFAOYSA-N 0.000 description 1
- QIKFRGIHLLQNBR-UHFFFAOYSA-N Ic(cc1)cc2c1[nH]cc2[IH]c1cc([nH]cc2)c2cc1 Chemical compound Ic(cc1)cc2c1[nH]cc2[IH]c1cc([nH]cc2)c2cc1 QIKFRGIHLLQNBR-UHFFFAOYSA-N 0.000 description 1
- RSGAXJZKQDNFEP-UHFFFAOYSA-N Ic1cc([nH]nc2)c2cc1 Chemical compound Ic1cc([nH]nc2)c2cc1 RSGAXJZKQDNFEP-UHFFFAOYSA-N 0.000 description 1
- CKPMCLJZMYZSHP-WMDOEDGGSA-N N#CN=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)/C=C/C1=C(O)C=CC=C1)CC2)C(=O)O)N1CC[C@H](O)C1 Chemical compound N#CN=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)/C=C/C1=C(O)C=CC=C1)CC2)C(=O)O)N1CC[C@H](O)C1 CKPMCLJZMYZSHP-WMDOEDGGSA-N 0.000 description 1
- WOZCTUAVSCIDIY-WCZSXJGWSA-N O=C(/C=C/C1=CC=C(SC2=CC(O[C@H]3CC[C@@H](C(=O)O)CC3)=CC=C2)C(C(F)(F)F)=C1C(F)(F)F)N1CCCCC1.O=C(/C=C/C1=CC=C(SC2=CC(O[C@H]3CC[C@H](C(=O)O)CC3)=CC=C2)C(C(F)(F)F)=C1C(F)(F)F)N1CCOCC1 Chemical compound O=C(/C=C/C1=CC=C(SC2=CC(O[C@H]3CC[C@@H](C(=O)O)CC3)=CC=C2)C(C(F)(F)F)=C1C(F)(F)F)N1CCCCC1.O=C(/C=C/C1=CC=C(SC2=CC(O[C@H]3CC[C@H](C(=O)O)CC3)=CC=C2)C(C(F)(F)F)=C1C(F)(F)F)N1CCOCC1 WOZCTUAVSCIDIY-WCZSXJGWSA-N 0.000 description 1
- QUCYWDQNRDFEIS-SFHVURJKSA-N O=C(CCC1=CC(Cl)=C(C(=O)N[C@@H](CNC(=O)C2=CC=CS2)C(=O)O)C(Cl)=C1)C1=CC(O)=CC=C1 Chemical compound O=C(CCC1=CC(Cl)=C(C(=O)N[C@@H](CNC(=O)C2=CC=CS2)C(=O)O)C(Cl)=C1)C1=CC(O)=CC=C1 QUCYWDQNRDFEIS-SFHVURJKSA-N 0.000 description 1
- UVWANQDLTNGRTO-OYKVQYDMSA-N O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)C(CO)N(C(=O)C1=CC=C(Cl)C=C1)CC2)C(=O)O)C1=CC=CS1 Chemical compound O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)C(CO)N(C(=O)C1=CC=C(Cl)C=C1)CC2)C(=O)O)C1=CC=CS1 UVWANQDLTNGRTO-OYKVQYDMSA-N 0.000 description 1
- WHGBQVUQKROPLI-QWNKOJSDSA-N O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)/C=C/C1=CC=CO1)CC2)C(=O)O)C1=CC=CS1 Chemical compound O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)/C=C/C1=CC=CO1)CC2)C(=O)O)C1=CC=CS1 WHGBQVUQKROPLI-QWNKOJSDSA-N 0.000 description 1
- LYOQZTDDLMKNKR-SFHVURJKSA-N O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC(Cl)=C(Cl)C=C1)CC2)C(=O)O)C1=CC=CS1 Chemical compound O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC(Cl)=C(Cl)C=C1)CC2)C(=O)O)C1=CC=CS1 LYOQZTDDLMKNKR-SFHVURJKSA-N 0.000 description 1
- PBWGNAKIFNSLLR-SFHVURJKSA-N O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC(Cl)=CC=C1)CC2)C(=O)O)C1=CC=CS1 Chemical compound O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC(Cl)=CC=C1)CC2)C(=O)O)C1=CC=CS1 PBWGNAKIFNSLLR-SFHVURJKSA-N 0.000 description 1
- FIPGXZKHGSKBRX-FQEVSTJZSA-N O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC(O)=NC3=C1C=CC=C3)CC2)C(=O)O)C1=CC=CS1 Chemical compound O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC(O)=NC3=C1C=CC=C3)CC2)C(=O)O)C1=CC=CS1 FIPGXZKHGSKBRX-FQEVSTJZSA-N 0.000 description 1
- SOLXJGUFQFXUAY-IBGZPJMESA-N O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC3=C(C=C1)C=NN3)CC2)C(=O)O)C1=CC=CS1 Chemical compound O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC3=C(C=C1)C=NN3)CC2)C(=O)O)C1=CC=CS1 SOLXJGUFQFXUAY-IBGZPJMESA-N 0.000 description 1
- HMHSDFNVSYBUNO-SFHVURJKSA-N O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC3=C(C=CC=C3)O1)CC2)C(=O)O)C1=CC=CS1 Chemical compound O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC3=C(C=CC=C3)O1)CC2)C(=O)O)C1=CC=CS1 HMHSDFNVSYBUNO-SFHVURJKSA-N 0.000 description 1
- FLXNWGWIXMCNFX-QFIPXVFZSA-N O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC3=C(C=CO3)C=C1)CC2)C(=O)O)C1=CC=CC(F)=C1 Chemical compound O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC3=C(C=CO3)C=C1)CC2)C(=O)O)C1=CC=CC(F)=C1 FLXNWGWIXMCNFX-QFIPXVFZSA-N 0.000 description 1
- WVTSKZKNRPBXCK-NRFANRHFSA-N O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C(Cl)C=C1)CC2)C(=O)O)C1=CC=CC=C1 Chemical compound O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C(Cl)C=C1)CC2)C(=O)O)C1=CC=CC=C1 WVTSKZKNRPBXCK-NRFANRHFSA-N 0.000 description 1
- MYOPIYULOOYNID-FQEVSTJZSA-N O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C3C=CNC3=C1)CC2)C(=O)O)C1=CC=CS1 Chemical compound O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C3C=CNC3=C1)CC2)C(=O)O)C1=CC=CS1 MYOPIYULOOYNID-FQEVSTJZSA-N 0.000 description 1
- VEAURVSVBGWAQH-SFHVURJKSA-N O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)NC1=CC(Cl)=CC=C1)CC2)C(=O)O)C1=CC=CS1 Chemical compound O=C(NC[C@H](NC(=O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)NC1=CC(Cl)=CC=C1)CC2)C(=O)O)C1=CC=CS1 VEAURVSVBGWAQH-SFHVURJKSA-N 0.000 description 1
- DDJGJQWKZJMZCL-SFHVURJKSA-N O=C(N[C@@H](CC1=CNC=N1)C(=O)O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C(Cl)C=C1)CC2 Chemical compound O=C(N[C@@H](CC1=CNC=N1)C(=O)O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C(Cl)C=C1)CC2 DDJGJQWKZJMZCL-SFHVURJKSA-N 0.000 description 1
- YRVSJJVTOBOIAT-SFHVURJKSA-N O=C(N[C@@H](CN1C=C(CO)N=N1)C(=O)O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C(Cl)C=C1)CC2 Chemical compound O=C(N[C@@H](CN1C=C(CO)N=N1)C(=O)O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C(Cl)C=C1)CC2 YRVSJJVTOBOIAT-SFHVURJKSA-N 0.000 description 1
- WXDNMARRENDDQI-QFIPXVFZSA-N O=C(N[C@@H](CNC1=NC=NC2=C1C=CC=C2)C(=O)O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C(Cl)C=C1)CC2 Chemical compound O=C(N[C@@H](CNC1=NC=NC2=C1C=CC=C2)C(=O)O)C1=C(Cl)C2=C(C=C1Cl)CN(C(=O)C1=CC=C(Cl)C=C1)CC2 WXDNMARRENDDQI-QFIPXVFZSA-N 0.000 description 1
- WBSXKVRTVMHGNY-YRNVUSSQSA-N O=C(O)C1CCC(OC2=CC=CC(SC3=CC=C(/C=C/C(=O)N4CCOCC4)C(C(F)(F)F)=C3C(F)(F)F)=C2)CC1 Chemical compound O=C(O)C1CCC(OC2=CC=CC(SC3=CC=C(/C=C/C(=O)N4CCOCC4)C(C(F)(F)F)=C3C(F)(F)F)=C2)CC1 WBSXKVRTVMHGNY-YRNVUSSQSA-N 0.000 description 1
- WBSXKVRTVMHGNY-BZZHFGAJSA-N OC([C@H](CC1)CC[C@H]1Oc1cccc(Sc2ccc(/C=C/C(N3CCOCC3)=O)c(C(F)(F)F)c2C(F)(F)F)c1)=O Chemical compound OC([C@H](CC1)CC[C@H]1Oc1cccc(Sc2ccc(/C=C/C(N3CCOCC3)=O)c(C(F)(F)F)c2C(F)(F)F)c1)=O WBSXKVRTVMHGNY-BZZHFGAJSA-N 0.000 description 1
- ZHJHVVJVYPNRRE-CTXKUHEWSA-N [H][C@@]12C(=C[C@H](C)C[C@@H]1OC(=O)[C@@H](C)CC)C=C[C@H](C)[C@@H]2CCC1C[C@@H](O)CC(=O)N1C1=C/C=C2\NC=C\C2=C\1.[H][C@@]12C(=C[C@H](C)C[C@@H]1OC(=O)[C@@H](C)CC)C=C[C@H](C)[C@@H]2CCC1C[C@@H](O)CC(=O)N1CC1=CC2=C(C=CC=C2)N=C1 Chemical compound [H][C@@]12C(=C[C@H](C)C[C@@H]1OC(=O)[C@@H](C)CC)C=C[C@H](C)[C@@H]2CCC1C[C@@H](O)CC(=O)N1C1=C/C=C2\NC=C\C2=C\1.[H][C@@]12C(=C[C@H](C)C[C@@H]1OC(=O)[C@@H](C)CC)C=C[C@H](C)[C@@H]2CCC1C[C@@H](O)CC(=O)N1CC1=CC2=C(C=CC=C2)N=C1 ZHJHVVJVYPNRRE-CTXKUHEWSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Cardiology (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/288,330 US20090155176A1 (en) | 2007-10-19 | 2008-10-17 | Compositions and methods for treatment of diabetic retinopathy |
US14/491,333 US9447077B2 (en) | 2008-04-15 | 2014-09-19 | Crystalline pharmaceutical and methods of preparation and use thereof |
US14/659,789 US10960087B2 (en) | 2007-10-19 | 2015-03-17 | Compositions and methods for treatment of diabetic retinopathy |
US15/235,572 US11028077B2 (en) | 2008-04-15 | 2016-08-12 | Crystalline pharmaceutical and methods of preparation and use thereof |
US17/181,187 US20210338839A1 (en) | 2007-10-19 | 2021-02-22 | Compositions and methods for treatment of diabetic retinopathy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99957107P | 2007-10-19 | 2007-10-19 | |
US12/288,330 US20090155176A1 (en) | 2007-10-19 | 2008-10-17 | Compositions and methods for treatment of diabetic retinopathy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/659,789 Continuation US10960087B2 (en) | 2007-10-19 | 2015-03-17 | Compositions and methods for treatment of diabetic retinopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090155176A1 true US20090155176A1 (en) | 2009-06-18 |
Family
ID=40579823
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/288,330 Abandoned US20090155176A1 (en) | 2007-10-19 | 2008-10-17 | Compositions and methods for treatment of diabetic retinopathy |
US14/659,789 Active US10960087B2 (en) | 2007-10-19 | 2015-03-17 | Compositions and methods for treatment of diabetic retinopathy |
US17/181,187 Abandoned US20210338839A1 (en) | 2007-10-19 | 2021-02-22 | Compositions and methods for treatment of diabetic retinopathy |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/659,789 Active US10960087B2 (en) | 2007-10-19 | 2015-03-17 | Compositions and methods for treatment of diabetic retinopathy |
US17/181,187 Abandoned US20210338839A1 (en) | 2007-10-19 | 2021-02-22 | Compositions and methods for treatment of diabetic retinopathy |
Country Status (9)
Country | Link |
---|---|
US (3) | US20090155176A1 (zh) |
EP (3) | EP3167886B1 (zh) |
JP (2) | JP5808037B2 (zh) |
CN (1) | CN101873797A (zh) |
AU (1) | AU2008317473B2 (zh) |
CA (3) | CA2958665C (zh) |
ES (2) | ES2830024T3 (zh) |
MX (1) | MX2010004281A (zh) |
WO (1) | WO2009054914A1 (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060281739A1 (en) * | 2005-05-17 | 2006-12-14 | Thomas Gadek | Compositions and methods for treatment of eye disorders |
US20080176896A1 (en) * | 2003-11-05 | 2008-07-24 | Wang Shen | Modulators of cellular adhesion |
US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
US20090258069A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Delivery of LFA-1 antagonists to the gastrointestinal system |
US20090258070A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Topical LFA-1 antagonists for use in localized treatment of immune related disorders |
US20090298869A1 (en) * | 2008-04-15 | 2009-12-03 | John Burnier | Crystalline pharmaceutical and methods of preparation and use thereof |
US20110092707A1 (en) * | 2009-10-21 | 2011-04-21 | Sarcode Corporation | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof |
US20110104206A1 (en) * | 2009-10-30 | 2011-05-05 | Intratus, Inc. | Methods and compositions for sustained delivery of drugs |
US20110189174A1 (en) * | 2010-02-01 | 2011-08-04 | Afshin Shafiee | Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization |
US20110281901A1 (en) * | 2010-05-05 | 2011-11-17 | Glaxo Wellcome Manufacturing Pte Ltd. | Pharmaceutical compositions and methods of making same |
US20130324603A1 (en) * | 2012-06-05 | 2013-12-05 | Olatec Industries Llc | Pharmaceutical composition for treating inflammation and pain |
US9085553B2 (en) | 2012-07-25 | 2015-07-21 | SARcode Bioscience, Inc. | LFA-1 inhibitor and methods of preparation and polymorph thereof |
US10960087B2 (en) | 2007-10-19 | 2021-03-30 | Novartis Ag | Compositions and methods for treatment of diabetic retinopathy |
US11018173B2 (en) | 2018-06-18 | 2021-05-25 | Samsung Electronics Co., Ltd. | Image sensor |
US11753382B2 (en) | 2019-06-25 | 2023-09-12 | Translatum Medicus Inc. | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112012024380A2 (pt) | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | compostos químicos |
EP2817018A4 (en) * | 2012-02-22 | 2015-09-23 | Stealth Peptides Int Inc | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS |
MA37756B1 (fr) | 2012-06-13 | 2018-09-28 | Hoffmann La Roche | Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane |
EP3590940B1 (en) | 2012-09-25 | 2021-06-09 | F. Hoffmann-La Roche AG | Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases |
AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
MA38982A1 (fr) | 2013-11-26 | 2017-09-29 | Hoffmann La Roche | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl |
JP6272604B2 (ja) * | 2013-12-27 | 2018-01-31 | 日本サプリメント株式会社 | 糖取り込み促進剤 |
MX2016010675A (es) | 2014-03-26 | 2016-11-10 | Hoffmann La Roche | Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa). |
CN106103446B (zh) | 2014-03-26 | 2019-07-30 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物 |
AR104177A1 (es) * | 2015-04-03 | 2017-07-05 | Santen Pharmaceutical Co Ltd | Sistema para la administración de fármacos en la glándula lagrimal |
CN108026077B (zh) | 2015-09-04 | 2021-11-05 | 豪夫迈·罗氏有限公司 | 苯氧基甲基衍生物 |
MA42923A (fr) | 2015-09-24 | 2021-04-28 | Hoffmann La Roche | Composés bicycliques comme inhibiteurs mixtes de atx/ca |
MA42918A (fr) | 2015-09-24 | 2018-08-01 | Hoffmann La Roche | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
JP6845230B2 (ja) | 2015-09-24 | 2021-03-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | デュアルatx/ca阻害剤としての新規な二環式化合物 |
WO2017050792A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
MA49879A (fr) | 2017-03-16 | 2020-06-24 | Hoffmann La Roche | Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca |
CN110382484B (zh) * | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
NZ762985A (en) | 2017-09-22 | 2024-03-22 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
HUE061607T2 (hu) | 2017-10-18 | 2023-07-28 | Jubilant Epipad LLC | Imidazopiridin vegyületek mint PAD inhibitorok |
CN111386265A (zh) | 2017-11-06 | 2020-07-07 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物 |
EP3704120B1 (en) | 2017-11-24 | 2024-03-06 | Jubilant Episcribe LLC | Heterocyclic compounds as prmt5 inhibitors |
BR112020018610A2 (pt) | 2018-03-13 | 2020-12-29 | Jubilant Prodel LLC | Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas |
BR112020021194A2 (pt) | 2018-04-18 | 2021-03-23 | Constallation Pharmaceuticals, Inc. | moduladores de enzimas modificadoras de metila, composições e usos dos mesmos |
CN112262143A (zh) | 2018-05-21 | 2021-01-22 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
WO2021247900A1 (en) * | 2020-06-05 | 2021-12-09 | Occurx Pty. Ltd. | Compounds and methods for the treatment of eye disorders |
IL302174A (en) * | 2020-10-21 | 2023-06-01 | Azura Ophthalmics Ltd | Compounds and methods for the treatment of eye disorders |
JP2024042677A (ja) * | 2022-09-15 | 2024-03-28 | 日油株式会社 | コンタクトレンズ用溶液 |
Citations (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
US4568343A (en) * | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
US4908202A (en) * | 1988-02-02 | 1990-03-13 | Cassella Aktiengesellschaft | Use of 2-oxo-1-pyrrolidineacetamide for the determination of the glomerular filtration rate in humans |
US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5134122A (en) * | 1989-07-28 | 1992-07-28 | Debiopharm S.A. | Method for preparing a pharmaceutical composition in the form of microparticles |
US5192741A (en) * | 1987-09-21 | 1993-03-09 | Debiopharm S.A. | Sustained and controlled release of water insoluble polypeptides |
US5288854A (en) * | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
US5298492A (en) * | 1992-08-04 | 1994-03-29 | Schering Corporation | Diamino acid derivatives as antihypertensives |
US5397791A (en) * | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5424289A (en) * | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
US5424399A (en) * | 1988-06-28 | 1995-06-13 | The Children's Medical Center Corporation | Human CR3α/β heterodimers |
US5597567A (en) * | 1991-10-04 | 1997-01-28 | The United States Of America As Represented By The Department Of Health And Human Services | Blocking cell adhesion molecules and treating animals with ocular inflammation |
US5612052A (en) * | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US5622700A (en) * | 1992-08-21 | 1997-04-22 | Genentech, Inc. | Method for treating a LFA-1-mediated disorder |
US5624837A (en) * | 1994-03-03 | 1997-04-29 | Alexion Pharmaceuticals, Inc. | Nucleic acid encoding chimeric complement inhibitor proteins |
US5747035A (en) * | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
US5863910A (en) * | 1996-01-12 | 1999-01-26 | Bolonick; Joel | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
US5893985A (en) * | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
US5922356A (en) * | 1996-10-09 | 1999-07-13 | Sumitomo Pharmaceuticals Company, Limited | Sustained release formulation |
US6011011A (en) * | 1992-09-21 | 2000-01-04 | Pharmacia & Upjohn Company | Sustained-release protein formulations |
US6180608B1 (en) * | 1996-12-11 | 2001-01-30 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
US6204280B1 (en) * | 1994-11-02 | 2001-03-20 | Merck Patent Gesellschaft Mit Berschrankter Haftung | Adhesion receptor antagonists |
US6203793B1 (en) * | 1992-02-28 | 2001-03-20 | Board Of Regents Of The University Of Texas System | Compositions and methods for treating thermal injury |
US20010006656A1 (en) * | 1999-02-17 | 2001-07-05 | University Of Washington | Methods and compositions for inhibiting inflammation associated with pulmonary disease |
US6340679B1 (en) * | 1999-02-13 | 2002-01-22 | Aventis Pharma Deutschland Gmbh | Guanidine derivatives as inhibitors of cell adhesion |
US6358976B1 (en) * | 1996-11-27 | 2002-03-19 | John Wityak | Integrin receptor antagonists |
US20020045582A1 (en) * | 1997-12-31 | 2002-04-18 | Alexey L. Margolin | Stabilized protein crystals formulations containing them and methods of making them |
US6515124B2 (en) * | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
US6521619B2 (en) * | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
US6524581B1 (en) * | 1998-12-30 | 2003-02-25 | The Children's Medical Center Corporation | Prevention and treatment of retinal ischemia and edema |
US20030044406A1 (en) * | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
US20030064105A1 (en) * | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
US20030069560A1 (en) * | 2001-05-03 | 2003-04-10 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
US20030138488A1 (en) * | 1999-12-31 | 2003-07-24 | Kohn Joachim B | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
US20040006236A1 (en) * | 1998-10-13 | 2004-01-08 | Nader Fotouhi | Diaminopropionic acid derivatives |
US20040009998A1 (en) * | 2001-10-01 | 2004-01-15 | Dhar T. G. Murali | Spiro-hydantoin compounds useful as anti-inflammatory agents |
US20040038973A1 (en) * | 2002-08-13 | 2004-02-26 | Joe Nahra | Phthalimide derivatives as matrix metalloproteinase inhibitors |
US6710064B2 (en) * | 2000-12-01 | 2004-03-23 | Bristol-Myers Squibb Co. | Hydantoin compounds useful as anti-inflammatory agents |
US20040058968A1 (en) * | 2000-11-28 | 2004-03-25 | Genentech, Inc. | LFA-1 antagonist compounds |
US20040122047A1 (en) * | 2001-06-06 | 2004-06-24 | Aventis Pharma Limited | Substituted tetrahydroisoquinolines |
US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US6867203B2 (en) * | 1998-12-29 | 2005-03-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
US6872382B1 (en) * | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
US20050107399A1 (en) * | 2003-09-11 | 2005-05-19 | Kemia, Inc. | Cytokine inhibitors |
US20050119279A1 (en) * | 2003-10-02 | 2005-06-02 | Dhar T. G. M. | Spiro-cyclic compounds useful as anti-inflammatory agents |
US20050142066A1 (en) * | 2002-06-06 | 2005-06-30 | Dana Farber Cancer Institute, Inc | Compounds or agents that inhibit and induce the formation of focal microvessel dilatations |
US20060052434A1 (en) * | 2004-08-18 | 2006-03-09 | Dhar T G M | Pyrrolizine compounds useful as anti-inflammatory agents |
US20060074099A1 (en) * | 2004-10-01 | 2006-04-06 | Delmonte Albert J | Crystalline forms and process for preparing spiro-hydantoin compounds |
US20060142319A1 (en) * | 2004-12-14 | 2006-06-29 | Bang-Chi Chen | Pyridyl-substituted spiro-hydantoin crystalline forms and process |
US20060148836A1 (en) * | 2004-12-14 | 2006-07-06 | Dhar T G M | Pyridyl-substituted spiro-hydantoin compounds and use thereof |
US7166568B1 (en) * | 1998-02-09 | 2007-01-23 | Oklahoma Medical Research Foundation | Compositions and methods to inhibit formation of the C5b-9 complex of complement |
US20070027101A1 (en) * | 2001-11-09 | 2007-02-01 | Guyer David R | Methods for treating ocular neovascular diseases |
US20070048216A1 (en) * | 2005-08-23 | 2007-03-01 | Norenberg Jeffrey P | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma |
US20070066585A1 (en) * | 2000-06-29 | 2007-03-22 | Wang Gary T | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
US20070090205A1 (en) * | 2005-06-24 | 2007-04-26 | Boehringer Ingelheim International Gmbh | Nebuliser and container |
US20070105824A1 (en) * | 2003-04-29 | 2007-05-10 | Erickson-Miller Connie L | Methods for treating degenerative diseases/injuries |
US20070142317A1 (en) * | 2003-12-29 | 2007-06-21 | Qlt Usa, Inc. | Topical composition for treatment of skin disorders |
US20070149593A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
US7314938B2 (en) * | 2003-11-05 | 2008-01-01 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
US20080108677A1 (en) * | 2004-08-30 | 2008-05-08 | Karyon-Ctt Ltd | Thioxothiazolidinone Compounds For Use As Pharmaceuticals |
US7396530B2 (en) * | 2004-06-09 | 2008-07-08 | Genentech, Inc. | Method of treating granuloma annulare or sarcoid |
US20100092541A1 (en) * | 2005-05-17 | 2010-04-15 | John Burnier | Compositions and methods for treatment of eye disorders |
US20110092707A1 (en) * | 2009-10-21 | 2011-04-21 | Sarcode Corporation | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof |
US20120107404A1 (en) * | 2008-04-15 | 2012-05-03 | Sarcode Bioscience Inc. | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US735A (en) | 1838-05-10 | Rtjftjg porter | ||
US6872A (en) | 1849-11-13 | Means of changing the combination in bevolving tumbler-locks | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
ES2064327T3 (es) | 1987-11-02 | 1995-02-01 | Baylor College Medicine | Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica. |
ATE90570T1 (de) | 1988-01-29 | 1993-07-15 | Sumitomo Pharma | Verbesserte formulierungen mit kontrollierter abgabe. |
EP0362526B1 (en) | 1988-08-23 | 1995-06-14 | Dana Farber Cancer Institute | The Alpha-subunit of the LFA-1 leukocyte adhesion receptor |
DE68929096T2 (de) | 1988-09-01 | 2000-05-11 | Bayer Ag | Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt |
AU4412889A (en) | 1988-09-28 | 1990-04-18 | Dana-Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
US5149780A (en) | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
EP0462184A4 (en) | 1989-03-09 | 1992-01-08 | Dana Farber Cancer Institute | Method of treating viral infections using lfa-1 |
WO1990013316A1 (en) | 1989-04-28 | 1990-11-15 | Baylor College Of Medicine | Dissemination of hiv-1 infected cells |
US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
WO1991019511A1 (en) | 1990-06-18 | 1991-12-26 | The General Hospital Corporation | CONTROLLING CELLULAR IMMUNE/INFLAMMATORY RESPONSES WITH β2 INTEGRINS |
CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
US5318965A (en) | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
EP0546077A1 (en) | 1990-08-27 | 1993-06-16 | Chiron Corporation | Cd18 peptide medicaments for the treatment of disease |
CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
WO1994011400A1 (en) | 1992-11-18 | 1994-05-26 | Helsinki University Licensing Ltd. Oy | Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis |
WO1994015587A2 (en) | 1993-01-06 | 1994-07-21 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
ATE192430T1 (de) | 1993-12-03 | 2000-05-15 | Hoffmann La Roche | Essigsäurederivate als arzneimittel |
US5470953A (en) | 1993-12-23 | 1995-11-28 | Icos Corporation | Human β2 integrin α subunit |
JPH09512021A (ja) | 1994-04-19 | 1997-12-02 | ザ ユニバーシティ オブ カンサス | Icam−1/lfa−1 短鎖ペプチドおよび該ペプチドの使用方法 |
US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
US5585359A (en) | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US20020028798A1 (en) | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
EP0828754B1 (en) | 1995-05-29 | 2005-02-02 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
US5843884A (en) | 1995-11-15 | 1998-12-01 | Oklahoma Medical Research Foundation | C9 complement inhibitor |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
US6319897B1 (en) | 1996-03-13 | 2001-11-20 | John D. Lambris | Peptides which inhibit complement activation |
IL126422A (en) | 1996-04-23 | 2004-02-19 | Kinerton Ltd | Biodegradable acidic polylactic polymers and methods for their preparation |
HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
AR012443A1 (es) | 1997-04-16 | 2000-10-18 | Uriach & Cia Sa J | Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos |
DE69839399T2 (de) | 1997-08-28 | 2009-05-20 | Novartis Ag | Lymphozyten funktion antigen-1 antagonisten |
IL138297A0 (en) | 1998-03-27 | 2001-10-31 | Genentech Inc | Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders |
CA2352389C (en) | 1998-11-27 | 2009-01-20 | Kanji Takada | An oral formulation for gastrointestinal drug delivery |
IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
WO2000040262A1 (en) | 1999-01-05 | 2000-07-13 | The Flinders University Of South Australia | Novel agents and methods for treatment and diagnosis of ocular disorders |
WO2000044731A1 (en) | 1999-01-27 | 2000-08-03 | G.D. Searle & Co. | Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors |
CO5140104A1 (es) | 1999-02-16 | 2002-03-22 | Novartis Ag | Derivados de mevinolina y preparacion farmaceuticas que los contienen |
CA2371940C (en) | 1999-03-31 | 2008-07-15 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
WO2000072883A2 (en) | 1999-06-02 | 2000-12-07 | Aviana Biopharm | Pharmaceutical transdermal compositions |
EP1194128A2 (en) | 1999-06-23 | 2002-04-10 | Sedum Laboratories | Ionically formulated biomolecule microcarriers |
ATE252915T1 (de) | 1999-08-18 | 2003-11-15 | Sod Conseils Rech Applic | Formulierung zur verzögerten freisetzung von peptiden |
ECSP003707A (es) | 1999-10-13 | 2002-05-23 | Novartis Ag | Diazepanes |
US6605597B1 (en) | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
US6294522B1 (en) | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
ATE403437T1 (de) | 1999-12-14 | 2008-08-15 | Genentech Inc | Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis |
EP1251864A4 (en) | 1999-12-31 | 2006-02-22 | Univ Rutgers | PHARMACEUTICAL FORMULATION COMPRISING A POLYMERIC MIXTURE AND AN ACTIVE COMPOUND FOR TIME-RELEASED RELEASE |
EP1263453A4 (en) | 1999-12-31 | 2008-02-20 | Univ Rutgers | PHARMACEUTICAL FORMULATION CONSISTING OF A POLYMERMATRIX, FOR REGULATING THE TIME-CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES |
DE60110396T2 (de) | 2000-01-14 | 2006-01-19 | Larson, Richard S., Albuquerque | Peptidische inhibitoren der lfa-1/icam-1 interaktion |
US6821986B2 (en) | 2000-05-05 | 2004-11-23 | Societe De Conseils De Recherchet Et E'applications Scientifiques (S.C.R.A.S.) | Amino acid derivatives and their use as medicines |
GB0011817D0 (en) | 2000-05-16 | 2000-07-05 | Pharmacia & Upjohn Spa | Antagonists of integrin receptors |
AR030817A1 (es) | 2000-10-02 | 2003-09-03 | Novartis Ag | Derivados de diazacicloalcanodiona |
GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
US6653478B2 (en) | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
DE10055857A1 (de) | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
GB0028367D0 (en) | 2000-11-21 | 2001-01-03 | Celltech Chiroscience Ltd | Chemical compounds |
WO2002050080A1 (en) | 2000-12-19 | 2002-06-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
WO2002058672A2 (en) | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
DE60216830T2 (de) | 2001-02-06 | 2007-06-14 | Pfizer Products Inc., Groton | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen |
AU2002258563A1 (en) | 2001-03-19 | 2002-10-03 | Praecis Pharmaceuticals Incorporated | Pharmaceutical formulations for sustained release |
US6391290B1 (en) | 2001-03-21 | 2002-05-21 | Schering-Plough Healthcare Products, Inc. | Skin care compositions |
CN1511151A (zh) | 2001-05-24 | 2004-07-07 | ֮����ҩ��ʽ���� | 3-喹啉-2(1h)-亚基二氢吲哚-2-酮衍生物 |
AU2002320352A1 (en) | 2001-07-24 | 2003-02-17 | Biogen Idec Ma Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
MXPA04006026A (es) | 2001-12-19 | 2005-03-31 | Alza Corp | Formulacion y forma de dosificacion para aumentar la biodisponibilidad oral de macromoleculas hidrofilitas. |
BR0308137A (pt) | 2002-03-04 | 2005-01-04 | Sod Conseils Rech Applic | Formulações de droga de liberação constante contendo um peptìdeo veìculo |
WO2004026406A1 (en) | 2002-09-20 | 2004-04-01 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
US7785578B2 (en) | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
EP2251434B1 (en) * | 2003-01-16 | 2014-07-30 | The Trustees of The University of Pennsylvania | Compositions and methods for siRNA inhibition of ICAM-1 |
WO2004073701A1 (ja) * | 2003-02-19 | 2004-09-02 | Kuniyasu Soda | Lfa-1抑制剤、及びその用途 |
US20050119186A1 (en) | 2003-07-22 | 2005-06-02 | Larson Richard S. | Potent peptide inhibitors and methods of use |
WO2005014534A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
CA2531796A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
WO2005042710A1 (en) | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of statin to kill ebv-transformed b cells |
UA86051C2 (en) | 2004-02-04 | 2009-03-25 | Пфайзер Продактс Инк. | Substituted quinoline compounds |
KR100799802B1 (ko) * | 2004-02-04 | 2008-01-31 | 화이자 프로덕츠 인크. | 치환된 퀴놀린 화합물 |
WO2005105766A2 (en) | 2004-04-28 | 2005-11-10 | Icos Corporation | Arylphenylamino-and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them |
GT200500139A (es) | 2004-06-08 | 2005-07-25 | Metodo para la preparacion de acidos hidroxamicos | |
US20060089590A1 (en) | 2004-10-27 | 2006-04-27 | John Higuchi | Methods and devices for sustained in-vivo release of an active agent |
US7943660B2 (en) | 2005-04-15 | 2011-05-17 | Dominion Pharmakine S.L. | Inhibitors of the LFA-1/ICAM-1 interaction and uses thereof |
US20060286108A1 (en) | 2005-06-16 | 2006-12-21 | Bell Katherine A | Topical compositions for the treatment of chronic wounds |
JP2007099641A (ja) * | 2005-09-30 | 2007-04-19 | Tsumura & Co | インドールキノキサリン類化合物、その製造方法およびそれを用いた医薬組成物 |
CA2624488A1 (en) * | 2005-10-06 | 2007-04-12 | Novartis Ag | Tetrahydro-pyrrolizinone compounds as lfa-i mediators |
GB0520378D0 (en) | 2005-10-06 | 2005-11-16 | Novartis Ag | Organic compounds |
ES2830024T3 (es) | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
ES2763703T3 (es) | 2008-04-15 | 2020-05-29 | Sarcode Bioscience Inc | Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes |
WO2009128932A1 (en) | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Delivery of lfa-1 antagonists to the gastrointestinal system |
-
2008
- 2008-10-17 ES ES16204718T patent/ES2830024T3/es active Active
- 2008-10-17 CA CA2958665A patent/CA2958665C/en active Active
- 2008-10-17 CA CA3105972A patent/CA3105972A1/en not_active Abandoned
- 2008-10-17 CN CN200880117716A patent/CN101873797A/zh active Pending
- 2008-10-17 US US12/288,330 patent/US20090155176A1/en not_active Abandoned
- 2008-10-17 EP EP16204718.7A patent/EP3167886B1/en active Active
- 2008-10-17 EP EP08842113.6A patent/EP2209371B1/en active Active
- 2008-10-17 EP EP20189143.9A patent/EP3797775A1/en not_active Withdrawn
- 2008-10-17 CA CA2702984A patent/CA2702984C/en active Active
- 2008-10-17 MX MX2010004281A patent/MX2010004281A/es active IP Right Grant
- 2008-10-17 ES ES08842113.6T patent/ES2630406T3/es active Active
- 2008-10-17 WO PCT/US2008/011878 patent/WO2009054914A1/en active Application Filing
- 2008-10-17 AU AU2008317473A patent/AU2008317473B2/en active Active
- 2008-10-17 JP JP2010529955A patent/JP5808037B2/ja active Active
-
2014
- 2014-07-14 JP JP2014144595A patent/JP2014221808A/ja active Pending
-
2015
- 2015-03-17 US US14/659,789 patent/US10960087B2/en active Active
-
2021
- 2021-02-22 US US17/181,187 patent/US20210338839A1/en not_active Abandoned
Patent Citations (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
US4568343A (en) * | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US5192741A (en) * | 1987-09-21 | 1993-03-09 | Debiopharm S.A. | Sustained and controlled release of water insoluble polypeptides |
US4908202A (en) * | 1988-02-02 | 1990-03-13 | Cassella Aktiengesellschaft | Use of 2-oxo-1-pyrrolidineacetamide for the determination of the glomerular filtration rate in humans |
US5424399A (en) * | 1988-06-28 | 1995-06-13 | The Children's Medical Center Corporation | Human CR3α/β heterodimers |
US5134122A (en) * | 1989-07-28 | 1992-07-28 | Debiopharm S.A. | Method for preparing a pharmaceutical composition in the form of microparticles |
US5288854A (en) * | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
US5597567A (en) * | 1991-10-04 | 1997-01-28 | The United States Of America As Represented By The Department Of Health And Human Services | Blocking cell adhesion molecules and treating animals with ocular inflammation |
US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US7323171B2 (en) * | 1991-10-07 | 2008-01-29 | Astellas Us Llc | Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction |
US6203793B1 (en) * | 1992-02-28 | 2001-03-20 | Board Of Regents Of The University Of Texas System | Compositions and methods for treating thermal injury |
US5298492A (en) * | 1992-08-04 | 1994-03-29 | Schering Corporation | Diamino acid derivatives as antihypertensives |
US5622700A (en) * | 1992-08-21 | 1997-04-22 | Genentech, Inc. | Method for treating a LFA-1-mediated disorder |
US20040120960A1 (en) * | 1992-08-21 | 2004-06-24 | Genentech, Inc. | Method for treating multiple sclerosis |
US6011011A (en) * | 1992-09-21 | 2000-01-04 | Pharmacia & Upjohn Company | Sustained-release protein formulations |
US5424289A (en) * | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
US5397791A (en) * | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5624837A (en) * | 1994-03-03 | 1997-04-29 | Alexion Pharmaceuticals, Inc. | Nucleic acid encoding chimeric complement inhibitor proteins |
US6204280B1 (en) * | 1994-11-02 | 2001-03-20 | Merck Patent Gesellschaft Mit Berschrankter Haftung | Adhesion receptor antagonists |
US5612052A (en) * | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US5747035A (en) * | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
US20030068384A1 (en) * | 1995-07-28 | 2003-04-10 | Stephen Brocchini | Polymeric drug formulations |
US20020019446A1 (en) * | 1995-07-28 | 2002-02-14 | Stephen Brocchini | Polymeric drug formulations |
US5863910A (en) * | 1996-01-12 | 1999-01-26 | Bolonick; Joel | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
US5922356A (en) * | 1996-10-09 | 1999-07-13 | Sumitomo Pharmaceuticals Company, Limited | Sustained release formulation |
US6358976B1 (en) * | 1996-11-27 | 2002-03-19 | John Wityak | Integrin receptor antagonists |
US6180608B1 (en) * | 1996-12-11 | 2001-01-30 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
US5893985A (en) * | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
US20020045582A1 (en) * | 1997-12-31 | 2002-04-18 | Alexey L. Margolin | Stabilized protein crystals formulations containing them and methods of making them |
US7166568B1 (en) * | 1998-02-09 | 2007-01-23 | Oklahoma Medical Research Foundation | Compositions and methods to inhibit formation of the C5b-9 complex of complement |
US20070155671A1 (en) * | 1998-10-13 | 2007-07-05 | Nader Fotouhi | Diaminopropionic acid derivatives |
US20050080119A1 (en) * | 1998-10-13 | 2005-04-14 | Nader Fotouhi | Diaminopropionic acid derivatives |
US20040006236A1 (en) * | 1998-10-13 | 2004-01-08 | Nader Fotouhi | Diaminopropionic acid derivatives |
US7217728B2 (en) * | 1998-10-13 | 2007-05-15 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
US6867203B2 (en) * | 1998-12-29 | 2005-03-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
US20080019977A1 (en) * | 1998-12-30 | 2008-01-24 | The Children's Medical Center Corporation | Prevention and treatment of retinal ischemia and edema |
US6524581B1 (en) * | 1998-12-30 | 2003-02-25 | The Children's Medical Center Corporation | Prevention and treatment of retinal ischemia and edema |
US20040028648A1 (en) * | 1998-12-30 | 2004-02-12 | The Children's Medical Center Corporation | Prevention and treatment of retinal ischemia and edema |
US6340679B1 (en) * | 1999-02-13 | 2002-01-22 | Aventis Pharma Deutschland Gmbh | Guanidine derivatives as inhibitors of cell adhesion |
US20010006656A1 (en) * | 1999-02-17 | 2001-07-05 | University Of Washington | Methods and compositions for inhibiting inflammation associated with pulmonary disease |
US20030138488A1 (en) * | 1999-12-31 | 2003-07-24 | Kohn Joachim B | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
US6515124B2 (en) * | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
US20070066585A1 (en) * | 2000-06-29 | 2007-03-22 | Wang Gary T | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
US6521619B2 (en) * | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
US20030064105A1 (en) * | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
US20040058968A1 (en) * | 2000-11-28 | 2004-03-25 | Genentech, Inc. | LFA-1 antagonist compounds |
US6872735B2 (en) * | 2000-11-28 | 2005-03-29 | Genentech, Inc. | LFA-1 antagonist compounds |
US20050148588A1 (en) * | 2000-11-28 | 2005-07-07 | Genentech, Inc. | LFA-1 antagonist compounds |
US6710064B2 (en) * | 2000-12-01 | 2004-03-23 | Bristol-Myers Squibb Co. | Hydantoin compounds useful as anti-inflammatory agents |
US20030044406A1 (en) * | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
US20070025990A1 (en) * | 2001-03-02 | 2007-02-01 | Medimmune, Inc. | Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
US20030068320A1 (en) * | 2001-03-02 | 2003-04-10 | Christine Dingivan | Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
US20030069560A1 (en) * | 2001-05-03 | 2003-04-10 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
US6872382B1 (en) * | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
US20040122047A1 (en) * | 2001-06-06 | 2004-06-24 | Aventis Pharma Limited | Substituted tetrahydroisoquinolines |
US7211586B2 (en) * | 2001-06-06 | 2007-05-01 | Aventis Pharma Limited | Substituted tetrahydroisoquinolines |
US20050004153A1 (en) * | 2001-10-01 | 2005-01-06 | Dhar T.G. Murali | Spiro-hydantoin compounds useful as anti-inflammatory agents |
US7078420B2 (en) * | 2001-10-01 | 2006-07-18 | Bristol-Myers Squibb Company | Spiro-hydantoin compounds useful as anti-inflammatory agents |
US20040009998A1 (en) * | 2001-10-01 | 2004-01-15 | Dhar T. G. Murali | Spiro-hydantoin compounds useful as anti-inflammatory agents |
US20070027101A1 (en) * | 2001-11-09 | 2007-02-01 | Guyer David R | Methods for treating ocular neovascular diseases |
US20050142066A1 (en) * | 2002-06-06 | 2005-06-30 | Dana Farber Cancer Institute, Inc | Compounds or agents that inhibit and induce the formation of focal microvessel dilatations |
US20040038973A1 (en) * | 2002-08-13 | 2004-02-26 | Joe Nahra | Phthalimide derivatives as matrix metalloproteinase inhibitors |
US20070105824A1 (en) * | 2003-04-29 | 2007-05-10 | Erickson-Miller Connie L | Methods for treating degenerative diseases/injuries |
US20050107399A1 (en) * | 2003-09-11 | 2005-05-19 | Kemia, Inc. | Cytokine inhibitors |
US7199125B2 (en) * | 2003-10-02 | 2007-04-03 | Bristol-Myers Squibb Company | Spiro-cyclic compounds useful as anti-inflammatory agents |
US20050119279A1 (en) * | 2003-10-02 | 2005-06-02 | Dhar T. G. M. | Spiro-cyclic compounds useful as anti-inflammatory agents |
US20080182839A1 (en) * | 2003-11-05 | 2008-07-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
US20080176896A1 (en) * | 2003-11-05 | 2008-07-24 | Wang Shen | Modulators of cellular adhesion |
US20100093693A1 (en) * | 2003-11-05 | 2010-04-15 | Wang Shen | Modulators of cellular adhesion |
US7928122B2 (en) * | 2003-11-05 | 2011-04-19 | Sarcode Corporation | Modulators of cellular adhesion |
US20110124669A1 (en) * | 2003-11-05 | 2011-05-26 | Sarcode Corporation | Modulators of Cellular Adhesion |
US7314938B2 (en) * | 2003-11-05 | 2008-01-01 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
US20070142317A1 (en) * | 2003-12-29 | 2007-06-21 | Qlt Usa, Inc. | Topical composition for treatment of skin disorders |
US7396530B2 (en) * | 2004-06-09 | 2008-07-08 | Genentech, Inc. | Method of treating granuloma annulare or sarcoid |
US20060052434A1 (en) * | 2004-08-18 | 2006-03-09 | Dhar T G M | Pyrrolizine compounds useful as anti-inflammatory agents |
US7375237B2 (en) * | 2004-08-18 | 2008-05-20 | Bristol-Myers Squibb Company | Pyrrolizine compounds useful as anti-inflammatory agents |
US20080108677A1 (en) * | 2004-08-30 | 2008-05-08 | Karyon-Ctt Ltd | Thioxothiazolidinone Compounds For Use As Pharmaceuticals |
US20060074099A1 (en) * | 2004-10-01 | 2006-04-06 | Delmonte Albert J | Crystalline forms and process for preparing spiro-hydantoin compounds |
US7381737B2 (en) * | 2004-10-01 | 2008-06-03 | Bristol-Myers Squibb Company | Crystalline forms and process for preparing spiro-hydantoin compounds |
US20060142319A1 (en) * | 2004-12-14 | 2006-06-29 | Bang-Chi Chen | Pyridyl-substituted spiro-hydantoin crystalline forms and process |
US20060148836A1 (en) * | 2004-12-14 | 2006-07-06 | Dhar T G M | Pyridyl-substituted spiro-hydantoin compounds and use thereof |
US7186727B2 (en) * | 2004-12-14 | 2007-03-06 | Bristol-Myers Squibb Company | Pyridyl-substituted spiro-hydantoin compounds and use thereof |
US20100092541A1 (en) * | 2005-05-17 | 2010-04-15 | John Burnier | Compositions and methods for treatment of eye disorders |
US20100092542A1 (en) * | 2005-05-17 | 2010-04-15 | John Burnier | Compositions and methods for treatment of eye disorders |
US8168655B2 (en) * | 2005-05-17 | 2012-05-01 | Sarcode Bioscience Inc. | Compositions and methods for treatment of eye disorders |
US20070090205A1 (en) * | 2005-06-24 | 2007-04-26 | Boehringer Ingelheim International Gmbh | Nebuliser and container |
US20070048216A1 (en) * | 2005-08-23 | 2007-03-01 | Norenberg Jeffrey P | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma |
US20070149593A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
US20120107404A1 (en) * | 2008-04-15 | 2012-05-03 | Sarcode Bioscience Inc. | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof |
US20130144063A1 (en) * | 2008-04-15 | 2013-06-06 | Sarcode Bioscience Inc. | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof |
US20110092707A1 (en) * | 2009-10-21 | 2011-04-21 | Sarcode Corporation | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof |
US20130150585A1 (en) * | 2009-10-21 | 2013-06-13 | SARcode Bioscience, Inc. | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof |
Non-Patent Citations (6)
Title |
---|
Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002 Apr;86(4):363-5. * |
Devine L, Lightman SL, Greenwood J. Role of LFA-1, ICAM-1, VLA-4 and VCAM-1 in lymphocyte migration across retinal pigment epithelial monolayers in vitro. Immunology. 1996 Jul;88(3):456-62. * |
King, F.D. (Ed.), "Bioisosteres, conformational restriction and pro-drugs--case history: an example of a conformational restriction approach," Medical Chemistry: Principles and Practice, 1994, Chapter 14, 206-209. * |
Meleth AD, Agrón E, Chan CC, Reed GF, Arora K, Byrnes G, Csaky KG, Ferris FL 3rd, Chew EY. Serum inflammatory markers Diabetologia. 2002 Dec;45(12):1617-34. in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4295-301. * |
Nam K1, Maiorov V, Feuston B, Kearsley S. Dynamic control of allosteric antagonism of leukocyte function antigen-1 and intercellular adhesion molecule-1 interaction. Proteins. 2006 Aug 1;64(2):376-84. * |
Porta M, Bandello F. Diabetic retinopathyA clinical update.Diabetologia. 2002 Dec;45(12):1617-34. * |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110124669A1 (en) * | 2003-11-05 | 2011-05-26 | Sarcode Corporation | Modulators of Cellular Adhesion |
US20080182839A1 (en) * | 2003-11-05 | 2008-07-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
US20110124625A1 (en) * | 2003-11-05 | 2011-05-26 | Sarcode Corporation | Modulators of Cellular Adhesion |
US8071617B2 (en) | 2003-11-05 | 2011-12-06 | Sarcode Bioscience Inc. | Modulators of cellular adhesion |
US9216174B2 (en) | 2003-11-05 | 2015-12-22 | Sarcode Bioscience Inc. | Modulators of cellular adhesion |
US9248126B2 (en) | 2003-11-05 | 2016-02-02 | Sarcode Bioscience Inc. | Modulators of cellular adhesion |
US20080176896A1 (en) * | 2003-11-05 | 2008-07-24 | Wang Shen | Modulators of cellular adhesion |
US20100093693A1 (en) * | 2003-11-05 | 2010-04-15 | Wang Shen | Modulators of cellular adhesion |
US7745460B2 (en) | 2003-11-05 | 2010-06-29 | Sarcode Corporation | Modulators of cellular adhesion |
US7790743B2 (en) | 2003-11-05 | 2010-09-07 | Sarcode Corporation | Modulators of cellular adhesion |
US7928122B2 (en) | 2003-11-05 | 2011-04-19 | Sarcode Corporation | Modulators of cellular adhesion |
US7989626B2 (en) | 2003-11-05 | 2011-08-02 | SAR code Corporation | Modulators of cellular adhesion |
US9045457B2 (en) | 2005-05-17 | 2015-06-02 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
US8592450B2 (en) | 2005-05-17 | 2013-11-26 | Sarcode Bioscience Inc. | Compositions and methods for treatment of eye disorders |
US9045458B2 (en) | 2005-05-17 | 2015-06-02 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
US8771715B2 (en) | 2005-05-17 | 2014-07-08 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
US8758776B2 (en) | 2005-05-17 | 2014-06-24 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
US9051297B2 (en) | 2005-05-17 | 2015-06-09 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
US10188641B2 (en) | 2005-05-17 | 2019-01-29 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
US20060281739A1 (en) * | 2005-05-17 | 2006-12-14 | Thomas Gadek | Compositions and methods for treatment of eye disorders |
US8168655B2 (en) | 2005-05-17 | 2012-05-01 | Sarcode Bioscience Inc. | Compositions and methods for treatment of eye disorders |
US8084047B2 (en) | 2005-05-17 | 2011-12-27 | Sarcode Bioscience Inc. | Compositions and methods for treatment of eye disorders |
US10960087B2 (en) | 2007-10-19 | 2021-03-30 | Novartis Ag | Compositions and methods for treatment of diabetic retinopathy |
US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US8367701B2 (en) | 2008-04-15 | 2013-02-05 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
US20090258069A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Delivery of LFA-1 antagonists to the gastrointestinal system |
US20090258070A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Topical LFA-1 antagonists for use in localized treatment of immune related disorders |
US20090298869A1 (en) * | 2008-04-15 | 2009-12-03 | John Burnier | Crystalline pharmaceutical and methods of preparation and use thereof |
US11028077B2 (en) | 2008-04-15 | 2021-06-08 | Novartis Pharmaceuticals Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
US8871935B2 (en) | 2008-04-15 | 2014-10-28 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US9353088B2 (en) * | 2009-10-21 | 2016-05-31 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US8927574B2 (en) | 2009-10-21 | 2015-01-06 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US20110092707A1 (en) * | 2009-10-21 | 2011-04-21 | Sarcode Corporation | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof |
US9890141B2 (en) | 2009-10-21 | 2018-02-13 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US20110104206A1 (en) * | 2009-10-30 | 2011-05-05 | Intratus, Inc. | Methods and compositions for sustained delivery of drugs |
US20110104083A1 (en) * | 2009-10-30 | 2011-05-05 | Intratus, Inc. | Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye |
US9034830B2 (en) | 2009-10-30 | 2015-05-19 | Intratus, Inc. | Methods and compositions for sustained delivery of drugs |
US20110189174A1 (en) * | 2010-02-01 | 2011-08-04 | Afshin Shafiee | Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization |
US20110281901A1 (en) * | 2010-05-05 | 2011-11-17 | Glaxo Wellcome Manufacturing Pte Ltd. | Pharmaceutical compositions and methods of making same |
US10751316B2 (en) | 2012-06-05 | 2020-08-25 | Olatec Therapeutics Llc | Pharmaceutical composition for treating inflammation and pain |
US20130324603A1 (en) * | 2012-06-05 | 2013-12-05 | Olatec Industries Llc | Pharmaceutical composition for treating inflammation and pain |
US9085553B2 (en) | 2012-07-25 | 2015-07-21 | SARcode Bioscience, Inc. | LFA-1 inhibitor and methods of preparation and polymorph thereof |
US10214517B2 (en) | 2012-07-25 | 2019-02-26 | Sarcode Bioscience Inc. | LFA-1 inhibitor and methods of preparation and polymorph thereof |
US10906892B2 (en) | 2012-07-25 | 2021-02-02 | Novartis Pharmaceuticals Corporation | LFA-1 inhibitor and methods of preparation and polymorph thereof |
US11018173B2 (en) | 2018-06-18 | 2021-05-25 | Samsung Electronics Co., Ltd. | Image sensor |
US11753382B2 (en) | 2019-06-25 | 2023-09-12 | Translatum Medicus Inc. | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
Also Published As
Publication number | Publication date |
---|---|
MX2010004281A (es) | 2010-09-10 |
EP2209371A1 (en) | 2010-07-28 |
ES2830024T3 (es) | 2021-06-02 |
CN101873797A (zh) | 2010-10-27 |
EP2209371B1 (en) | 2017-01-04 |
AU2008317473A1 (en) | 2009-04-30 |
CA2702984A1 (en) | 2009-04-30 |
AU2008317473B2 (en) | 2014-07-17 |
ES2630406T3 (es) | 2017-08-21 |
WO2009054914A1 (en) | 2009-04-30 |
CA2958665C (en) | 2021-03-02 |
EP2209371A4 (en) | 2011-11-02 |
JP2014221808A (ja) | 2014-11-27 |
CA2958665A1 (en) | 2009-04-30 |
US10960087B2 (en) | 2021-03-30 |
US20210338839A1 (en) | 2021-11-04 |
EP3797775A1 (en) | 2021-03-31 |
JP5808037B2 (ja) | 2015-11-10 |
EP3167886A1 (en) | 2017-05-17 |
CA3105972A1 (en) | 2009-04-30 |
US20160220702A1 (en) | 2016-08-04 |
CA2702984C (en) | 2017-04-11 |
EP3167886B1 (en) | 2020-08-05 |
JP2011500683A (ja) | 2011-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210338839A1 (en) | Compositions and methods for treatment of diabetic retinopathy | |
US20230233551A1 (en) | Compositions and methods for treatment | |
AU2014208186A1 (en) | Compositions and methods for treatment of diabetic retinopathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SARCODE CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BURNIER, JOHN;GADEK, THOMAS;SEMBA, CHARLES;REEL/FRAME:022167/0029 Effective date: 20081201 |
|
AS | Assignment |
Owner name: SARCODE BIOSCIENCE INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:SARCODE CORPORATION;REEL/FRAME:026876/0312 Effective date: 20110715 |
|
AS | Assignment |
Owner name: SILICON VALLEY BANK, CALIFORNIA Free format text: SECURITY AGREEMENT;ASSIGNOR:SARCODE BIOSCIENCE INC.;REEL/FRAME:029778/0888 Effective date: 20130208 |
|
AS | Assignment |
Owner name: SARCODE BIOSCIENCE INC., CALIFORNIA Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:SILICON VALLEY BANK;REEL/FRAME:030295/0028 Effective date: 20130424 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SARCODE BIOSCIENCE INC.;REEL/FRAME:050900/0268 Effective date: 20190701 |